Anticoagulation in atrial fibrillation: the present and the future

Abstract

Atrial fibrillation (AF) is the most common form of cardiac arrhythmia and associated with significant mortality and morbidity. It is a powerful predictor of future embolic stroke, such that anticoagulation is recommended in the majority of patients. For many years this has predominantly been in the form of vitamin K antagonists. However, there are well-documented difficulties with their administration that result in poor compliance and high discontinuation rates. Over recent years several oral alternative anticoagulant agents have become available with the potential to overcome many of these pitfalls. In this review, we discuss current recommendations for anticoagulant therapy in AF and how these may change in the future with the introduction of novel therapeutic options.